

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

NCT05514327

| | |
|-------------------|---------------------------------------|
| Status | RECRUITING |
| Phase | Not Applicable |
| Sponsor | Peking Union Medical College Hospital |
| Enrollment | 20 participants |

Key Eligibility Criteria

Inclusion (6)

- Over than 18 years old
- Histologically confirmed DLBCL(by central pathology review before enrolment)
- Relapsed or refractory disease after e2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
- Measurable disease at time of enrollment (the maximum diameter of cross section e1.5cm)
- Life expectancy e12 weeks

... and 1 more (see full listing online)

Exclusion (7)

- Prior radiation therapy within 1 year of infusion
- Pregnant or nursing (lactating) women
- Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive d 72 hours prior to infusion)
- Previous solid tumor within 3 years, previous or concurrent hematological malignancy
- Severe organ dysfunction: left ventricle ejection fraction (LVEF) $\leq 40\%$; DLCO $\leq 40\%$; estimated glomerular filtration rate (eGFR) $\leq 30\text{mL}/\text{min}/1.73\text{ m}^2$; total bilirubin $\geq 3\text{ ULN}$

... and 2 more (see full listing online)

Locations (1 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China